Treatment of Post-Obstructive Pneumonia

Initial Antibiotic Selection

The American College of Physicians and Infectious Diseases Society of America recommends combination therapy with a β-lactam plus macrolide or monotherapy with a respiratory fluoroquinolone for hospitalized patients without ICU admission 1, 2
The Infectious Diseases Society of America suggests that preferred regimens include amoxicillin-clavulanate plus a macrolide, ceftriaxone plus azithromycin, or levofloxacin as monotherapy 1, 2, 3
The addition of anaerobic coverage is critical in post-obstructive pneumonia, making amoxicillin-clavulanate or ampicillin-sulbactam superior to other β-lactams in this setting 3

The Infectious Diseases Society of America recommends parenteral β-lactam with antipseudomonal activity plus either a fluoroquinolone or macrolide for severe cases requiring ICU admission 2, 4
Antipseudomonal regimens include piperacillin-tazobactam plus levofloxacin, cefepime, imipenem, or meropenem plus ciprofloxacin or levofloxacin 2, 4

The Infectious Diseases Society of America recommends that the first antibiotic dose be administered in the emergency department without delay, as mortality increases with treatment delays 1, 2
Parenteral therapy should be initiated for all hospitalized patients with moderate-to-severe disease, and switched to oral therapy when the patient is hemodynamically stable and clinically improving 1, 2, 5

The Infectious Diseases Society of America recommends that treatment continue for a minimum of 5 days and until the patient has been afebrile for 48-72 hours with no more than one sign of clinical instability 1, 2

The Infectious Diseases Society of America recommends obtaining sputum cultures or bronchoscopic samples before initiating antibiotics when possible, as pathogen-directed therapy improves outcomes 1, 5
Once a pathogen is identified, narrow therapy to target that organism specifically, and consider bronchoscopic quantitative cultures for ventilated patients 1, 2, 4

The American College of Physicians and Infectious Diseases Society of America warns against underestimating anaerobic involvement, failing to address the obstruction, inadequate Pseudomonas coverage, premature discontinuation, and development of resistant organisms 1, 2, 3, 4, 6

For patients with prior intravenous antibiotic use within 90 days or structural lung disease, the Infectious Diseases Society of America recommends prescribing antibiotics from two different classes with activity against Pseudomonas aeruginosa 7
The Infectious Diseases Society of America suggests adding MRSA coverage (vancomycin or linezolid) if the patient received intravenous antibiotics in the prior 90 days or if treated in a unit where MRSA prevalence among S. aureus isolates exceeds 20% 7
If MRSA coverage is omitted, the Infectious Diseases Society of America recommends ensuring the regimen includes coverage for methicillin-sensitive S. aureus (MSSA) 7